摘要
Prostate cancer （PCa） is the most common solid-organ cancer in American males and the second most common cause of cancer-related death in men. With the advent of prostate-specific antigen screening, death from PCa continues to decline. However, recent evidence suggests that there is now a trend towards increasing incidence.1 Current screening strategies result in increased incidence of low-risk PCa and importantly, the diagnosis of PCa is becoming more common in younger patients.2 The majority of early-stage PCa patients have a high likelihood of disease free survival after treatment.
Prostate cancer （PCa） is the most common solid-organ cancer in American males and the second most common cause of cancer-related death in men. With the advent of prostate-specific antigen screening, death from PCa continues to decline. However, recent evidence suggests that there is now a trend towards increasing incidence.1 Current screening strategies result in increased incidence of low-risk PCa and importantly, the diagnosis of PCa is becoming more common in younger patients.2 The majority of early-stage PCa patients have a high likelihood of disease free survival after treatment.
